Trial Profile
An observational, retrospective-prospective, multicenter cohort study evaluating efficacy and safety of Safinamide as an adjunctive treatment in patients with Parkinson' s disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2018
Price :
$35
*
At a glance
- Drugs Safinamide (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- 28 Nov 2018 New trial record
- 09 Oct 2018 Results presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders